Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Telomir Pharmaceuticals Touts Promising Action From Its Lead Breast Cancer Drug

cancer

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) stock is trading higher on Thursday, with a session volume of 21.60 million compared to the average volume of 4.9 million, as per data from Benzinga Pro.

The company announced new findings demonstrating that its lead drug candidate, Telomir-1, significantly decreases the viability of aggressive triple-negative breast cancer (TNBC) cells – a highly invasive form of breast cancer.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.